Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2016 | Can biosimilars ensure access to drugs for everyone?

Robin Foà • 9 Jun 2016
EHA 2016
General

Robin Foà, MD from the Sapienza University, Rome, Italy discusses whether biosimilars may help increase the access to novel drugs. Prof. Foà points out that the saving might be around 30% of the original drug cost, which means that biosimilars would not necessarily make novel drugs accessible everywhere. Biosimilars are a step forward but they will not solve the problem according to Prof. Foà.
Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.

More from Robin Foà

8:11
The José Carreras award and a history of immunotherapy in Ph+ ALL
Robin Foà • 11 Jun 2023
3:22
The evolution of therapy for Ph+ ALL and Ph- ALL & the role of MRD in this space
Robin Foà • 11 Jun 2023
2:36
Investigating the incidence and outcomes of CNS relapse in patients with ALL
Robin Foà • 23 Mar 2023
10:05
Chemotherapy-free regimens in Ph+ ALL: where are we now and where are we headed?
Robin Foà • 23 Mar 2023

Related Videos

1:08
Chronological age no longer dictates eligibility for allogeneic transplantation in patients with MDS
Didier Blaise • 4 Apr 2024
1:24
The future of CAR T-reg cells: organ transplantation & autoimmune disease
Zinaida Good • 9 Apr 2024
2:44
Do biomarkers exist for predicting response to CAR T-cell therapy?
Marco Ruella • 9 Apr 2024
2:43
Resistance to CAR T-cell therapy
Marco Ruella • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals